Navigation Links
Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association

vements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. In particular, there can be no guarantee that additional information relating to the safety, efficacy or tolerability of satraplatin may be discovered upon further analysis of data from the SPARC trial or analysis of additional data from other ongoing clinical trials for satraplatin. Furthermore, we cannot guarantee that satraplatin will be approved for marketing in a timely manner, if at all, by regulatory authorities nor that, if marketed, satraplatin will be a successful commercial product. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2005, Pharmion's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, its most recent filings on Form 10-Q and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of either Pharmion or GPC Biotech. Forward-looking statements speak only as of the date on which they are made and neither Pharmion nor GPC Biotech undertakes any obligation to update these forward-looking statements, even if new information becomes available in the future.

Satraplatin has not yet been approved by the FDA in the U.S., the EMEA in Europe or any other regulatory authority and no conclusions can or should be drawn regarding its safety or effectiveness. Only the relevant regulatory authorities can determine whether satraplatin is safe and effective for the use(s) being investigated.

Taxotere(R) (docetaxel) is a registered trademark of Aventis Pharma S.A.

CONTACT: GPC Biotech AG - Martin Braendle, Director, Investor Relat
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:7/23/2014)... , July 23, 2014 Inovio ... successful results from its randomized, double-blind, placebo-controlled ... with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) ... or 18. Treatment with VGX-3100, Inovio,s HPV16/18-specific ... to CIN1 or no disease, meeting the ...
(Date:7/23/2014)...  The management team at Columbia Laboratories, Inc. ... conference call on July 31, 2014, to discuss ... 30, 2014.  The call details are as follows:Date: ... EDTDial-in numbers: , Toll free: (877) 870-4263 (U.S.), ... archive): , www.columbialabs.com , under ,Investor, or ...
(Date:7/23/2014)... Global healthcare company GSK reports ... headwinds, increased price competition and supply disruptions to its ... points out that the company is very much in ... be confident about long-term prospects as well as the ... CFO Simon Dingemans adds that the company ...
Breaking Medicine Technology:Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2
... SPRING, Md., June 20, 2011 The U.S. Food ... help advance the development and approval of an artificial ... United States. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... condition in which the pancreas produces little or no ...
... (NYSE Amex: CUR ) announced that it has ... Phase Ia trial to test the safety of NSI-189 for ... drug in healthy volunteers for safety and tolerability. NSI-189 is ... new neuron growth in the hippocampus, an area of the ...
Cached Medicine Technology:FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System 2FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System 3Neuralstem Updates NSI-189 Major Depression Trial 2Neuralstem Updates NSI-189 Major Depression Trial 3
(Date:7/23/2014)... on human cancer genes have been focused on the ... be translated in the form of amino acids thus ... regulatory region or activator which controls the expression and ... was known of the role exerted such DNA fragment ... in Nature in collaboration with the group ...
(Date:7/23/2014)... Irvine, Calif., July 23, 2014 A therapy combining ... of a gene inhibitor into the brain restored voluntary ... UC Irvine,s Reeve-Irvine Research Center have found. , In ... achieved this breakthrough by turning back the developmental clock ... corticospinal tract nerve connections and providing a scaffold so ...
(Date:7/23/2014)... This report defines and segments the ... the Middle East & Africa, and Americas) - Global ... with analysis and forecasts of the global revenue. The ... over $10 billion in 2014 to nearly $14 billion ... , browse 49 Market Tables and 10 Figures Spread ...
(Date:7/23/2014)... A Forever Recovery, an open-ended drug and ... great start and gives them a solid foundation in ... Internet Addiction section of its website at http://aforeverrecovery.com/behavioral-addictions/internet-addiction/ ... Internet addiction is not just as legitimate a disorder ... trapping more and more victims each year – particularly ...
(Date:7/23/2014)... Children and teens who lose a parent might face an ... study suggests. People who were children or teens when ... death during the study period than those who had not ... Although the study found an association between a parent,s ... wasn,t designed to prove cause-and-effect. Also, the increased risk ...
Breaking Medicine News(10 mins):Health News:Gene inhibitor, salmon fibrin restore function lost in spinal cord injury 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 3Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 4Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2
... significantly slow or halt science's ability to establish ... by industry, a team of scientists and lawyers ... caution that litigation's effects could seriously impair efforts ... variety of diseases, including Parkinson's disease, Alzheimer's disease ...
... blood flow to the brain, helps the bodies detoxify ... Alzheimer's, say researchers. ,"Exercise improves thinking and mental ... associate professor of medicine at the New York University ... Health Central. ,"Studies have shown that it works ...
... and PRK eye procedures are safe and effective, according ... recent American Academy of Ophthalmology’s //Joint Meeting. ,Researchers ... PRK treatments say both procedures provide stable, long term ... answer to those who doubt LASIK’s reliability, showing that ...
... big, juicy steak for dinner last night, adding a large amount ... For one in ten of us, that could be a big ... our diet, our bodies use it for energy. But patients with ... of Americans – are more likely to develop arthrosclerosis, or build-up ...
... the age when reading a newspaper means holding ... glasses, wavefront-optimized //lens technology may offer a better ... American Academy of Ophthalmology’s 2006 Joint Meeting. ... lenses developed using wavefront technology offer significant improvements ...
... Blaming the resurfacing of polio cases in the Indian ... //Delhi Chief Minister Sheila Dikshit Saturday said that around ... part of the Pulse Polio programme. ,"Delhi was ... occurrence of fresh cases, mostly due to migration of ...
Cached Medicine News:Health News:Fast-Multiplying Lawsuits Can Stymie Medical Science, Authors Warn 2Health News:Fast-Multiplying Lawsuits Can Stymie Medical Science, Authors Warn 3Health News:PRK and LASIK Surgeries ‘Safe and Effective 2Health News:Sugars in Liver Found to Clear Fats from the Bloodstream 2Health News:Beyond Bifocals: Wavefront Technology Benefits Patients With Presbyopia 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: